Quoin Pharmaceuticals Bolsa (NASDAQ: QNRX)

Últimas noticias sobre Quoin Pharmaceuticals (NASDAQ:QNRX) Bolsa

Quoin Pharmaceuticals

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals Ltd

Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) has outperformed the market over the past 10 years by 8.48% on an annualized basis producing an average annual return of 19.96%. Currently, Adobe has a market capitalization of $192.41 billion. 
Buying $100 In ADBE: If an investor had bought $100 of ADBE stock 10 years ago, it would be worth $620.13 today based on a price of $442.00 for ADBE at the time of writing.
<h3>Adobe's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738275401_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

ADBE

Here's How Much $100 Invested In Adobe 10 Years Ago Would Be Worth Today

Earnings

RBKB

Rhinebeck Bancorp Q4 EPS $(0.25), Down From $0.09 YoY

Shore Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHBI#NASDAQ">SHBI</a>) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.35 by 14.29 percent. This is a 25 percent increase over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $44.01 million which beat the analyst consensus estimate of $43.55 million by 1.06 percent. This is a 5.99 percent increase over sales of $41.52 million the same period last year.

Earnings Beats

SHBI

Shore Bancshares Q4 2024 GAAP EPS $0.40 Beats $0.35 Estimate, Sales $44.01M Beat $43.55M Estimate

Helix, a decentralized exchange built on Injective (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/inj/usd">INJ</a>), has launched an AI Index Perpetual Market, a product that allows investors to gain on-chain exposure to both AI-focused crypto tokens <a href="https://www.benzinga.com/money/best-artificial-intelligence-stocks">and traditional equities.</a>
This launch marks a significant step in bringing traditional financial instruments into the decentralized finance (DeFi) space by offering exposure to a curated selection of ten AI tokens and six AI equities, such as NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
The Helix AI Index futures market is designed to help investors track portfolio performance in a sector that is blending both tech and crypto. 
The AI index ensures that no single asset dominates, and by diversifying between both crypto tokens and traditional equities, the risk of poor performance from any one asset is reduced. 
Real-time updates and historical data also enables investors to more accurately track trends and inform their investment decisions.
Meredith Pitkoff, CEO and Co-founder of Stork Labs said, &#8220;Products like the Helix AI Index are what decentralized finance was conceived for," adding that, "Collaborating on this index is also our first foray in creating a product that combines equity and crypto markets together into one aggregate index.&#8221;
The Stork Oracle powers the Helix AI Index, which is adjusted on a monthly basis to reflect current market positions. 
Stork initially determines the index's value from data gathered from centralized market's crypto tokens, then assigns the price based on each asset's market capitalization. 
The index's weights will then automatically rebalance based on real-time market dynamics.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43316599/cme-group-expands-crypto-offerings-with-options-on-bitcoin-friday-futures">CME Group Expands Crypto Offerings With Options On Bitcoin Friday Futures</a>
Speaking with Benzinga, Injective CEO Eric Chen said the Helix AI Index shows "what Helix is built to do—democratize access to sophisticated financial instruments." 
He also stated that this launch enables "borderless, permissionless access for investors" to traditional equities for the first time.
When asked about the challenges of institutional adoption of on-chain products, he responded that &#8220;the evolving political and regulatory landscape is creating new opportunities for institutions to engage with on-chain assets." 
He also emphasized the need for more transparent and globally accessible financial products, adding that "platforms like Helix will be instrumental in bridging the gap between legacy finance and the next generation of digital markets."
Chen also commented on the potential for decentralized perpetual markets to compete with traditional financial instruments. 
He stated that liquidity fragmentation is one of DeFi&#8217;s biggest hurdles, and that decentralized markets need to "evolve toward more shared liquidity models, enabling deeper markets and more efficient trading." 
He added that, "Injective is poised to lead—by offering seamless cross-chain liquidity and interoperability.&#8221; 
This has been helped by Injective's native EVM integration, allowing EVM developers to tap into the shared liquidity model that exists within the Injective network.
Helix has witnessed tremendous growth in 2024, and is now consistently ranked as one of the largest perpetual DEXs on the market, with an average of $2 billion in volume across 100 million trades every month.
The listed tokens and equities will launch with the following weights:&nbsp;
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>AI Tokens: Near (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/near/usd">NEAR</a>): 11.19% Internet Computer (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ICP</a>): 8.66% Bittensor (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TAO</a>): 7.39% Render (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">RENDER</a>): 6.55% Artificial Superintelligence Alliance (CRYPTO: CRYPTO: FET): 5.91% Injective (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/inj/usd">INJ</a>): 3.80% Virtuals Protocol (CRYPTO: VIRTUALS): 2.85% Ai16z (CRYPTO: AI16Z): 1.46% Akash Network (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">AKT</a>): 1.29% Grass (CRYPTO: GRASS): 0.91%</td>
<td>AI Equities: NVIDIA: 36.34% Taiwan Semiconductor Manufacturing Company Ltd: 9.68% Palantir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>): 2.10% Arista Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIT#NASDAQ">ANIT</a>): 1.56% Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>): 0.21%SenseTime (SNTMF): 0.10% </td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43314878/coinbase-taps-trumps-campaign-manager-chris-lacivita-to-tackle-crypto-policy-in-washington">Coinbase Taps Trump&#8217;s Campaign Manager, Chris LaCivita To Tackle Crypto Policy In Washington</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$AKT

$ICP

$INJ

$NEAR

$RENDER

$TAO

ANIT

NVDA

PLTR

SMCI

Helix Debuts AI Index Perpetual Market, Bridging Crypto And Traditional Equities On-Chain

FLIC

The First Of Long Island Q4 EPS $0.14, Down From $0.27 YoY

Telsey Advisory Group analyst Joseph Feldman maintains Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) with a Outperform and maintains $67 price target.

Price Target

Analyst Ratings

TSCO

Telsey Advisory Group Maintains Outperform on Tractor Supply, Maintains $67 Price Target

Stellar Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEL#NYSE">STEL</a>) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.49 by 6.12 percent. This is a 5.45 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $107.99 million which beat the analyst consensus estimate of $107.45 million by 0.50 percent. This is a 4.28 percent decrease over sales of $112.82 million the same period last year.

STEL

Stellar Bancorp Q4 GAAP EPS $0.52 Beats $0.49 Estimate, Sales $107.99M Beat $107.45M Estimate

Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) reported its third-quarter financial results after Thursday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/01/b43352442/deckers-brands-reports-third-quarter-fiscal-year-2025-financial-results"> from the report. </a>
The Details: Deckers Outdoor reported quarterly earnings of $3 per share which beat the analyst consensus estimate of $2.55. Quarterly revenue came in at $1.83 billion which beat the analyst consensus estimate of $1.73 billion and is an increase over sales of $1.56 billion from the same period last year.
<ul>
<li>UGG brand net sales increased 16.1% to $1.24 billion compared to $1.07 billion.</li>
<li>HOKA brand net sales increased 23.7% to $530.9 million compared to $429.3 million.</li>
<li>Teva brand net sales decreased 6% to $24.1 million compared to $25.6 million.</li>
<li>Other brands net sales decreased 16.6% to $28.0 million compared to $33.6 million.</li>
<li>Direct-to-Consumer (DTC) net sales increased 17.9% to $1.01 billion compared to $858.1 million. DTC comparable net sales increased 18.3%.</li>
<li>Wholesale net sales increased 16.2% to $815.8 million compared to $702.2 million.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/general/travel/25/01/43343648/all-60-passengers-4-crew-members-onboard-american-airlines-jet-feared-dead-after-midair-collision-official-says">64 Killed In American Airlines Midair Collision Near D.C., Worst US Air Disaster Since 2001&nbsp;</a>
&#8220;Deckers posted exceptional results in the third quarter, delivering record quarterly revenue, gross margin, and earnings,&#8221; said Stefano Caroti, CEO of Deckers Outdoor. 
&#8220;UGG continued to experience incredible global momentum, with the brand&#8217;s iconic franchises capturing strong full price consumer demand across all regions. At the same time, HOKA delivered impressive results consistent with our strategy, remaining focused on scaling through innovative performance products,&#8221; Caroti added. &nbsp;
Outlook:&nbsp;Deckers Outdoor sees fiscal 2025 revenue growth of 15% and fiscal 2025 earnings of between $5.75 and $5.80 per share, versus the $5.54 estimate. 
DECK Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Deckers shares are down 16.18% after hours at $187.80 Thursday at publication.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43320124/microsoft-shares-slide-after-q2-results-cloud-revenue-misses-expectations-details">Microsoft Shares Slide After Q2 Results, Cloud Revenue Misses Expectations: Details</a>&nbsp;</li>
</ul>
Image: Shutterstock

Guidance

After-Hours Center

Movers

DECK

Deckers Outdoor Shares Clobbered Despite Strong Q3 Results Led By UGG, HOKA Brands

Macquarie analyst Tim Nollen maintains Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) with a Neutral and maintains $30 price target.

Macquarie Maintains Neutral on Warner Music Gr, Maintains $30 Price Target

Baker Hughes Says It Remains Confident In Achieving 20% EBITDA Margin Targets For OFSE This Year And IET In 2026

Macquarie analyst Tim Nollen maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Outperform and raises the price target from $500 to $600.

SPOT

Macquarie Maintains Outperform on Spotify Technology, Raises Price Target to $600

Baker Hughes Expects 2025 To Demonstrate Another Strong Year Of EBITDA Growth, Led By IET Segment

Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.63 by 11.11 percent. This is a 37.25 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $7.36 billion which beat the analyst consensus estimate of $7.08 billion by 4.04 percent. This is a 7.74 percent increase over sales of $6.83 billion the same period last year.

Baker Hughes Q4 2024 Adj EPS $0.70 Beats $0.63 Estimate, Sales $7.36B Beat $7.08B Estimate

Across the recent three months, 4 analysts have shared their insights on AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $10.25, with a high estimate of $11.00 and a low estimate of $9.50. This current average represents a 2.38% decrease from the previous average price target of $10.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1738274475_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive AGNC Investment. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Jason Weaver</td>
<td>Jones Trading</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.25</td>
<td>$10.25</td>
</tr>
<tr>
<td>Bose George</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$10.25</td>
<td>$10.75</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.50</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to AGNC Investment. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of AGNC Investment compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of AGNC Investment's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into AGNC Investment's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AGNC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AGNC Investment analyst ratings.</a>
<h2>Discovering AGNC Investment: A Closer Look</h2>
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
<h3>AGNC Investment: Delving into Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Challenges: AGNC Investment's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -59.04%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 55.84%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): AGNC Investment's ROE stands out, surpassing industry averages. With an impressive ROE of 1.06%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.1%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGNC

Assessing AGNC Investment: Insights From 4 Financial Analysts

Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $18.73, a high estimate of $24.00, and a low estimate of $16.00. Witnessing a positive shift, the current average has risen by 19.76% from the previous average price target of $15.64.
<img src="https://www.benzinga.com/files/images/story/2025/1738274465_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Upwork by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kunal Madhukar</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Marvin Fong</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$18.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Upwork. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Upwork compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Upwork's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Upwork's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UPWK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Upwork analyst ratings.</a>
<h2>About Upwork</h2>
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to clients.
<h3>Financial Milestones: Upwork's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Upwork displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 10.27%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Upwork's net margin is impressive, surpassing industry averages. With a net margin of 14.32%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Upwork's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.68%, the company showcases effective utilization of assets.
Debt Management: Upwork's debt-to-equity ratio is below the industry average at 0.9, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UPWK

Breaking Down Upwork: 11 Analysts Share Their Views

Ratings for Crane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $175.75, with a high estimate of $200.00 and a low estimate of $157.00. This upward trend is evident, with the current average reflecting a 2.03% increase from the previous average price target of $172.25.
<img src="https://www.benzinga.com/files/images/story/2025/1738274456_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Crane. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Summerville</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$170.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$157.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Hold</td>
<td>$176.00</td>
<td>$176.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Crane. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Crane compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Crane's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Crane's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Crane analyst ratings.</a>
<h2>Delving into Crane's Background</h2>
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
<h3>Unraveling the Financial Story of Crane</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Crane faced challenges, resulting in a decline of approximately -8.89% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Crane's net margin excels beyond industry benchmarks, reaching 14.89%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Crane's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 5.04%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Crane's ROA excels beyond industry benchmarks, reaching 3.07%. This signifies efficient management of assets and strong financial health.
Debt Management: Crane's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.15.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Crane Stands With Analysts

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for BlackLine, revealing an average target of $71.3, a high estimate of $86.00, and a low estimate of $60.00. Witnessing a positive shift, the current average has risen by 9.69% from the previous average price target of $65.00.
<img src="https://www.benzinga.com/files/images/story/2025/1738274443_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive BlackLine is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koji Ikeda</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Maintains</td>
<td>Buy</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$86.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Chris Quintero</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$51.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BlackLine. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BlackLine compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of BlackLine's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into BlackLine's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on BlackLine analyst ratings.</a>
<h2>About BlackLine</h2>
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their financial close process including account reconciliations, variance analysis of account balances, journal entry capabilities, and certain types of data matching capabilities. The majority of the revenue of the company is earned in the United States.
<h3>BlackLine's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: BlackLine's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 10.09%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: BlackLine's net margin is impressive, surpassing industry averages. With a net margin of 10.39%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.97%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): BlackLine's ROA excels beyond industry benchmarks, reaching 0.96%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.49, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 10 Analysts Discuss BlackLine Stock

4 analysts have shared their evaluations of UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $141.5, a high estimate of $156.00, and a low estimate of $128.00. This current average reflects an increase of 8.02% from the previous average price target of $131.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738274429_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of UMB Financial among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$128.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Nathan Race</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$139.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Brian Wilczynski</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$156.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UMB Financial. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of UMB Financial compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of UMB Financial's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UMBF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on UMB Financial analyst ratings.</a>
<h2>Unveiling the Story Behind UMB Financial</h2>
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking, asset management, and health spending solutions. Its customer base includes commercial, institutional, and personal customers across the United States. The company's banking subsidiaries own and operate banking and wealth-management centers mostly throughout the Midwest and Southwest regions of the U.S. Subsidiaries of the holding company and its lead bank, UMB Bank, include mutual fund and alternative investment services groups, single-purpose companies that deal with brokerage services and insurance, and a registered investment advisory. The bank's revenue is split nearly evenly between interest income and noninterest income.
<h3>UMB Financial's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: UMB Financial's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 8.32%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 30.44%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): UMB Financial's ROE stands out, surpassing industry averages. With an impressive ROE of 3.43%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.25%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: UMB Financial's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UMBF

A Glimpse Into The Expert Outlook On UMB Financial Through 4 Analysts

Barrington Research analyst James Goss maintains Sirius XM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) with a Outperform and maintains $30 price target.

SIRI

Barrington Research Maintains Outperform on Sirius XM Holdings, Maintains $30 Price Target

8 analysts have shared their evaluations of Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $24.62, along with a high estimate of $39.00 and a low estimate of $16.00. Observing a 15.15% increase, the current average has risen from the previous average price target of $21.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1738274416_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Pacira BioSciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$25.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pacira BioSciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Pacira BioSciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Pacira BioSciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Pacira BioSciences</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Financial Insights: Pacira BioSciences</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Pacira BioSciences's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 2.83%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Pacira BioSciences's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -85.11%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Pacira BioSciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -17.62%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -9.06%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PCRX

What 8 Analyst Ratings Have To Say About Pacira BioSciences

Maxim Group is acting as the exclusive placement agent for this offering. Published first on TheFly – the ultimate source for real-time, market-mov...

Quoin Pharmaceuticals files to sell 19.23M ordinary shares

Quoin Pharmaceuticals announces 19.23M equity offering

Quoin Pharmaceuticals (QNRX) announces interim clinical data from two of its ongoing Netherton Syndrome clinical studies. Data from the first subje...

Quoin Pharmaceuticals announces interim data from Netherton Syndrome studies

Quoin Pharmaceuticals (QNRX) announces FDA clearance to initiate a new additional Netherton Syndrome clinical study for QRX003. QRX003 is a topical...

Quoin Pharmaceuticals announces FDA clearance to initiate QRX003 study

Quoin Pharmaceuticals (QNRX) announced the pricing of its "reasonable best efforts" public offering of 15,111,110 ordinary shares represented by 15...

Quoin Pharmaceuticals prices 15.1M ADSs at 45c in public offering

Quoin Pharmaceuticals announces pricing of $6.8 million public offering

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report), with a price...

Buy Rating Reaffirmed for Quoin Pharmaceuticals Amid Promising QRX003 Developments and Market Potential

Quoin Pharmaceuticals (QNRX) announces interim clinical data from its ongoing Investigator Pediatric Netherton Syndrome clinical study. The Investi...

Quoin announces clinical data from ongoing Pediatric Netherton Syndrome study

Quoin Pharmaceuticals (QNRX) announces further clinical evidence of the potential efficacy of QRX003 in Netherton Syndrome. In December 2024 and Ja...

Quoin Pharmaceuticals announces further clinical evidence on QRX003 efficacy

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report) and keeping the price target at $2.00...

Quoin Pharmaceuticals: Buy Rating Affirmed Amidst Potential First-Mover Advantage in Netherton Syndrome Treatment

QNRX

Health Care

Press Releases

General

Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Financing

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials

Comments

Quoin Pharmaceuticals

Noticias

Últimas noticias sobre Quoin Pharmaceuticals (NASDAQ:QNRX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL